KPV: The Quieting Tail of a Hormone

The short version

KPV is one of the smallest peptides in this literature — just three amino acids: lysine, proline, valine. It is the final three residues of a hormone called alpha-melanocyte-stimulating hormone (alpha-MSH), and its defining property in the scientific record is that it keeps the parent hormone's anti-inflammatory power while leaving behind its skin-darkening (pigment) effect ^[5].

Unlike classical immune therapies, KPV does not act primarily through melanocortin receptors. Instead it enters inflamed intestinal lining cells directly via the PepT1 transporter and suppresses the molecular switches — NF-kB and MAP kinase pathways — that drive inflammatory cytokine production ^[3]. Most of its research is in animal models of colitis. Be clear-eyed about the stage: there are no published human clinical trials of KPV. It is sold for laboratory research only, it is not an approved drug or supplement, and this page lists no human dose.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11-13 — the C-terminal sequence — of alpha-MSH. You will also see it written as alpha-MSH(11-13). The molecular formula is C16H30N4O4. Although it derives from a melanocortin hormone, its defining feature in the literature is anti-inflammatory activity without the pigmentary (melanogenic) action of the full parent peptide ^[5]. It carries no approved drug or supplement status in any major jurisdiction and is handled as a research chemical for laboratory use.

How it works

KPV dampens inflammation by suppressing two master switches inside cells: the transcription factor NF-kB and the MAP-kinase signaling pathways. Blocking these reduces the production and secretion of pro-inflammatory cytokines such as IL-1beta and TNF-alpha ^[3].

There is a structurally interesting delivery mechanism in the gut. The peptide is small enough to be carried directly into intestinal epithelial cells by a di/tripeptide transporter called PepT1 (gene SLC15A1), and PepT1 expression is upregulated in inflamed intestinal tissue — meaning the transport route is most active precisely where inflammation is highest ^[3]. At nanomolar concentrations, KPV taken up this way reduced NF-kB and MAPK activation and lowered cytokine secretion in human intestinal epithelial cell lines and T cells in culture ^[3].

Notably, the anti-inflammatory effect persisted in mice lacking the MC1R receptor, confirming that KPV acts through an MC1R-independent mechanism and is not simply a backdoor melanocortin agonist ^[4]. A separate mechanistic analysis further delineated KPV's anti-inflammatory action as distinct from the core MSH peptides — likely directed against IL-1beta function rather than through receptor-mediated cytokine suppression common to those peptides ^[7].

What the research shows

Cellular mechanism and acute colitis. The foundational study established PepT1-mediated uptake of KPV into human intestinal epithelial cell lines and Jurkat T cells, with nanomolar KPV inhibiting NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion; oral KPV then reduced the severity of both DSS- and TNBS-induced colitis in C57BL/6 mice ^[3].

Colitis recovery and MC1R independence. In murine DSS and adoptive-transfer colitis models, KPV-treated mice showed earlier recovery, stronger regain of body weight, reduced colonic inflammatory infiltrate, and lower myeloperoxidase activity. The effect was retained in MC1R-deficient mice, demonstrating an MC1R-independent anti-inflammatory route ^[4].

Targeted oral delivery. Because free KPV is fragile, recent work has focused on formulation. Orally administered hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue and reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing ^[2]. A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond what either agent achieved alone ^[1].

Corneal wound healing. Topical KPV accelerated corneal epithelial wound healing in rabbits; by 60 hours, 8 of 8 KPV-treated corneas were fully re-epithelialized versus none in the placebo group, an effect linked to a nitric-oxide-dependent mechanism ^[6].

Broad anti-inflammatory review. A comprehensive review of alpha-MSH and related tripeptides documents KPV and related peptides showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models, explicitly delineating KPV as the anti-inflammatory option that lacks pigmentary action ^[5].

Reported effects, cautions & safety

There are no real-world community-use reports or human clinical data for KPV compiled in this desk's source material. The characterization below comes entirely from the preclinical research record.

The cautions are dominated by one central fact — the evidence base is entirely preclinical:

• No human trials. No published human clinical trials of KPV exist; the entire efficacy literature is in vitro and animal (chiefly murine colitis), so human dosing, efficacy and safety are unestablished ^[3].
• Fragility and no human pharmacokinetics. Free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetic data — which is exactly why so much of the field's recent effort goes into formulations designed to keep it intact long enough to act ^[2].
• Marketing outruns evidence. Promotion of KPV for gut health, skin health, or general anti-inflammatory use runs ahead of a literature that is mechanistic and preclinical, not clinical.
• Not a tanning peptide. Although KPV is derived from alpha-MSH, it should be clearly distinguished from melanocortin agonists used for skin pigmentation; its defining characteristic in the literature is anti-inflammatory action without pigment effect ^[5].
• Research-use status only. KPV is available from chemical suppliers for laboratory research use only and is not an approved drug or dietary supplement in any jurisdiction.

Where it fits in immune research

Among the two peptides on this desk, KPV is the peripheral anti-inflammatory signal — working at the site of inflammation by suppressing cytokine-driving transcription factors rather than through central thymic programming ^[3]. Its evidence is entirely preclinical, but its mechanism is among the most precisely mapped in the small-peptide anti-inflammatory field: a specific transporter, a specific signaling pathway, and an MC1R-independent route that separates it cleanly from tanning peptides ^[4]. See how it compares to Thymulin on the comparison page.